Table 1.
LRIG1 copy number ratios and clinicopathological characteristics of the breast cancer cohort
| Characteristic | Lossa | Normala | Gaina | P-value* |
|---|---|---|---|---|
| Number of patients (N = 423 | 77 (18.2%) | 293 (69.3%) | 53 (12.5%) | |
| Age at diagnosis (years; mean ± SD) | 55.7 ± 13.3 | 60.1 ± 11.54 | 62.5 ± 13.42 | |
| Age ≤ 60 (N = 211) | 46 (21.8%) | 142 (67.3%) | 23 (10.9%) | 0.125 |
| Age > 60 (N = 212) | 31 (14.6%) | 151 (71.2%) | 30 (14.2%) | |
| Steroid receptor status | < 0.001 | |||
| Negative (N = 117) | 39 (33.3%) | 65 (55.6%) | 13 (11.1%) | |
| Positive (N = 306) | 38 (12.4%) | 228 (74.5%) | 40 (13.1%) | |
| ERBB2status | 0.002 | |||
| Negative (N = 336) | 50 (14.9%) | 245 (72.9%) | 41 (12.2%) | |
| Positive (N = 87) | 27 (31.0%) | 48 (55.2%) | 12 (13.8%) | |
| Tumor subtype | < 0.001 | |||
| ERBB2+, ER/PR- (N = 45) | 16 (35.6%) | 23 (51.1%) | 6 (13.3%) | |
| ERBB2+, ER/PR+ (N = 42) | 11 (26.2%) | 25 (59.5%) | 6 (14.3%) | |
| ERBB2-, ER/PR+ (N = 264) | 27 (10.2%) | 203 (76.9%) | 34 (12.9%) | |
| ERBB2-, ER/PR- (N = 72) | 23 (31.9%) | 42 (58.3%) | 7 (9.7%) | |
| Disease stage (N = 278; missing data = 145) | 0.151 | |||
| I (N = 109) | 18 (16.5%) | 84 (77.1%) | 7 (6.4%) | |
| II (N = 131) | 28 (21.4%) | 85 (64.9%) | 18 (13.7%) | |
| III (N = 7) | 1 (14.3%) | 5 (71.4%) | 1 (14.3%) | |
| IV (N = 31) | 6 (19.4%) | 17 (54.8%) | 8 (25.8%) | |
| Tumor grade (N = 363, missing data = 60) | 0.004 | |||
| I (N = 31) | 1 (3.2%) | 25 (80.6%) | 5 (16.1%) | |
| II (N = 137) | 15 (10.9%) | 104 (75.9%) | 18 (13.1%) | |
| III (N = 195) | 50 (25.6%) | 120 (61.5%) | 25 (12.8%) | |
| Tumor size (N = 329, missing data = 94) | 0.158 | |||
| Size ≤20 mm (N = 154) | 29 (18.8%) | 111 (72.1%) | 14 (9.1%) | |
| Size > 20 mm (N = 175) | 37 (21.1%) | 111 (63.4%) | 27 (15.4%) | |
| Nodal status (N = 360, missing data = 63) | 0.001 | |||
| Negative (N = 279) | 43 (15.4%) | 207 (74.2%) | 29 (10.4%) | |
| Positive (N = 81) | 24 (29.6%) | 43 (53.1%) | 14 (17.3%) | |
| Tumor types | 0.041 | |||
| Ductal (N = 354) | 66 (18.6%) | 237 (66.9%) | 51 (14.4%) | |
| Lobular (N = 35) | 5 (14.3%) | 30 (85.7%) | 0 (0.0%) | |
| Others (N = 34) | 6 (17.6%) | 26 (76.5%) | 2 (5.9%) | |
aLRIG1/CYP1B1 ratio < 0.85, loss; 0.85–1.15, normal; > 1.15, gain
*The overall P values are from comparisons between all LRIG1 loss, LRIG1 normal and LRIG1 gain groups. Significance was calculated by the 2-sided Fisher’s exact test